Search

Your search keyword '"Ribero, S."' showing total 822 results
Start Over Author "Ribero, S."
822 results on '"Ribero, S."'

3. The Skin Microbiome and Its Role in Psoriasis: A Review

Author

Celoria V, Rosset F, Pala V, Dapavo P, Ribero S, Quaglino P, and Mastorino L

Subjects
psoriasis, skin microbiome, new therapies, gut microbioma, molecular precision medicines, next generation treatments., Dermatology, RL1-803
Abstract

Valentina Celoria,* Francois Rosset,* Valentina Pala, Paolo Dapavo, Simone Ribero, Pietro Quaglino, Luca Mastorino Dermatologic Clinic, Department of Medical Sciences, University of Turin, Turin, Italy*These authors contributed equally to this workCorrespondence: Valentina Celoria, Dermatologic Clinic, Department of Medical Sciences, University of Turin, Turin, Italy, Email valentina.celoria@edu.unito.itAbstract: The skin microbiome is made of various microorganisms, most of which have the function of protecting individuals from harmful pathogens, and they are involved in innate and adaptive immune responses. The skin acts as a physical and immunological barrier against external stimuli, including pathogens and physical damage. Changes in the composition of the skin microbiome can trigger inflammatory processes leading to inflammatory skin diseases in susceptible individuals. Psoriasis (PsO) is a chronic inflammatory disease with a multifactorial etiology, where breakdown of immune tolerance to cutaneous microorganisms is implicated in its pathogenesis. Dysregulation of the microbiome due to genetic and environmental factors plays a significant role in the development of psoriatic disease. Dermatologic conditions such as atopic dermatitis, acne, psoriasis, and rosacea have been associated with intestinal dysbiosis. The skin microbiota composition is crucial for the development of appropriate immune responses, and alterations in the skin microbiome can contribute to changes in physiology and susceptibility to skin diseases or inflammatory conditions. Understanding the microbial settlement of the skin and the network of interactions that occur throughout life is essential for comprehending the pathogenesis of skin diseases and developing innovative treatments. With this article we tried to explore the relationship between the human microbiome and psoriatic disease, shedding light on the functions of the microbiome and the inflammatory disease processes to identify additional therapeutic targets. This review aims to highlight the relationship between skin and gut microbiome functions and inflammatory processes in skin psoriasis and psoriatic arthritis (PsA). The goal is to facilitate future studies on the skin microbiome to identify potential novel therapies for patients with psoriatic disease.Keywords: psoriasis, skin microbiome, new therapies, gut microbiome, molecular precision medicines, next generation treatments

Published
2023

4. [Translated article] Multicenter Analysis of the Surgical Management and Adjuvant Therapy of Patients With Melanoma and a Positive Sentinel Lymph Node Biopsy

Author

Samaniego-González, E., Podlipnik, S., Ribero, S., Nagore, E., Boada, A., Cañueto, J., Paradela, S., de Unamuno, B., Rodríguez-Jiménez, P., Puig, S., Malvehy, J., Carrera, C., Roccuzzo, G., Requena, C., Manrique-Silva, E., Richarz, N., Ruiz-Villanueva, A., Traves, V., España-Fernández, S., Botella-Estrada, R., González-Morán, M.A., and Tejera-Vaquerizo, A.

Published
2024
Full Text
View/download PDF

5. Análisis multicéntrico del manejo quirúrgico y tratamiento adyuvante de los pacientes con melanoma y positividad en la biopsia selectiva del ganglio centinela

Author

Samaniego-González, E., Podlipnik, S., Ribero, S., Nagore, E., Boada, A., Cañueto, J., Paradela, S., de Unamuno, B., Rodríguez-Jiménez, P., Puig, S., Malvehy, J., Carrera, C., Roccuzzo, G., Requena, C., Manrique-Silva, E., Richarz, N., Ruiz-Villanueva, A., Traves, V., España-Fernández, S., Botella-Estrada, R., González-Morán, M.A., and Tejera-Vaquerizo, A.

Published
2024
Full Text
View/download PDF

6. Folliculotropic Mycosis Fungoides: Current Guidance and Experience from Clinical Practice

Author

Roccuzzo G, Mastorino L, Gallo G, Fava P, Ribero S, and Quaglino P

Subjects
mycosis fungoides, folliculotropic mycosis fungoides, cutaneous lymphoma, primary cutaneous t-cell lymphoma, therapy, Dermatology, RL1-803
Abstract

Gabriele Roccuzzo,* Luca Mastorino,* Giuseppe Gallo, Paolo Fava, Simone Ribero, Pietro Quaglino Department of Medical Sciences, Section of Dermatology, University of Turin, Turin, Italy*These authors contributed equally to this workCorrespondence: Giuseppe Gallo, Department of Medical Sciences, Section of Dermatology, University of Turin, Via Cherasco 23, Torino, Turin, 10126, Italy, Tel +39 0116335843 ; +39 0116335034, Email giuseppegallomd@gmail.comIntroduction: Folliculotropic mycosis fungoides (FMF) is the most frequent variant of mycosis fungoides (MF), with clinical features which differ from the classic form. As for therapeutic options, the latest guidelines on MF agree on a stage-driven strategy, in consideration of clinical presentation, symptom burden and patient’s comorbidities.Materials and Methods: A search on MEDLINE, PubMed, Scopus and Cochrane Library was conducted to gather the latest evidence on FMF clinical management. Manuscripts published in the last five years (January 2017–April 2022) were included. Our single-center experience was also described.Results: A total of 15 articles were analyzed, with a total of 432 patients (disease stage from IA to IVA2). The most widely-used treatment was psoralen ultra-violet A (PUVA) in monotherapy or in association with other drugs. Oral retinoid-based therapy was also described as a therapeutic option alone or in combination. Other therapy reported were based on Brentuximab Vedotin, Mogamulizumab, Carmustine, topical steroids, tazarotene and excimer laser, interferon, nitrogen mustard, imiquimod, systemic chemotherapy, extracorporeal photopheresis and stem cell transplantation.Discussion: FMF is characterized by specific clinical-pathologic features. Advanced forms assume characteristics more similar to classic MF (infiltrated plaques and nodules), whilst early stages can present in a wide range of clinical forms (acneiform lesions, follicular-like keratoses, erythematous patches). As for therapeutic options, in absence of specific guidelines, a high number of treatments are described in clinical practice, with variable results. Phototherapy in all its forms, especially as PUVA, appears to have the greatest initial therapeutic success. Retinoids, although widely used, appear to be poorly effective in monotherapy, particularly acitretin. Combination treatment with phototherapy seems to be advisable. Ionizing treatments, such as radiotherapy and TSEBT, appear effective, at least in the short term. Overall, an integrated approach is mandatory for the inconstant course of the disease and its multidisciplinary nature.Keywords: mycosis fungoides, folliculotropic mycosis fungoides, cutaneous lymphoma, primary cutaneous T-cell lymphoma, therapy

Published
2022

7. Clinicopathological definition, management and prognostic value of mogamulizumab‐associated rash and other cutaneous events: A systematic review.

Author

Avallone, G., Roccuzzo, G., Pileri, A., Agostinelli, C., Maronese, C. A., Aquino, C., Tavoletti, G., Onida, F., Fava, P., Ribero, S., Marzano, A. V., Berti, E., Quaglino, P., and Alberti‐Violetti, S.

Subjects
PROGNOSIS, SEZARY syndrome, PHOTOSENSITIVITY disorders, DIAGNOSIS, MONOCLONAL antibodies
Abstract

Mogamulizumab is a first‐in‐class IgG1k monoclonal antibody that selectively targets the chemokine receptor type 4. The drug has received Food and Drug administration authorisation for mycosis fungoides and Sézary syndrome following failure of at least one previous course of systemic therapy and now is available in Europe. One of the most common treatment‐related side effects observed has been the mogamulizumab‐associated rash (MAR), which affects up to a quarter of patients and is the most frequent adverse event leading to drug discontinuation. The aim of this study is to perform a systematic review of the literature on patients diagnosed with MAR and other mogamulizumab‐related cutaneous events to describe the clinical and histological characteristics, the management in clinical practice and to assess whether these events have prognostic implications. In total, 2073 records were initially identified through a literature search, 843 of which were duplicates. After screening for eligibility and inclusion criteria, 49 articles reporting mogamulizumab‐associated cutaneous events were included. Totally, 1516 patients were retrieved, with a slight male prevalence as for the available data (639 males and 570 females, i.e. 52.9% vs. 47.1%). Regarding the reported clinicopathological findings of the cutaneous reactions, the five most common patterns were spongiotic/psoriasiform dermatitis (22%), eruptions characterized by the presence of papules and/or plaques (16.1%), cutaneous granulomatosis (11.4%), morbilliform or erythrodermic dermatitis (9.4%) and photodermatitis (7.1%). Our results highlight how the majority of the reported cutaneous adverse events on mogamulizumab are of mild‐to‐moderate entity and generally manageable in clinical practice, though prompt recognition is essential and case‐by‐case assessment should be recommended. Future research will need to focus on the MAR prognostic implications and to identify genomic and molecular markers for a more rapid and accurate diagnosis. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

11. Fast Clinical Response of Bimekizumab in Nail Psoriasis: A Retrospective Multicenter 36-Week Real-Life Study

Author

Campione, E, Artosi, F, Shumak, R, Giunta, A, Argenziano, G, Assorgi, C, Balato, A, Bernardini, N, Brunasso, A, Burlando, M, Caldarola, G, Campanati, A, Carugno, A, Castelli, F, Conti, A, Costanzo, A, Cuccia, A, Dapavo, P, Dattola, A, De Simone, C, Di Lernia, V, Dini, V, Donini, M, Errichetti, E, Esposito, M, Fargnoli, M, Foti, A, Fiorella, C, Gargiulo, L, Gisondi, P, Guarneri, C, Legori, A, Lembo, S, Loconsole, F, Malagoli, P, Marzano, A, Mercuri, S, Megna, M, Micali, G, Mortato, E, Musumeci, M, Narcisi, A, Offidani, A, Orsini, D, Paolino, G, Pellacani, G, Peris, K, Potenza, C, Prignano, F, Quaglino, P, Ribero, S, Richetta, A, Romanelli, M, Rossi, A, Strippoli, D, Trovato, E, Venturini, M, Bianchi, L, Campione, Elena, Artosi, Fabio, Shumak, Ruslana Gaeta, Giunta, Alessandro, Argenziano, Giuseppe, Assorgi, Chiara, Balato, Anna, Bernardini, Nicoletta, Brunasso, Alexandra Maria Giovanna, Burlando, Martina, Caldarola, Giacomo, Campanati, Anna, Carugno, Andrea, Castelli, Franco, Conti, Andrea, Costanzo, Antonio, Cuccia, Aldo, Dapavo, Paolo, Dattola, Annunziata, De Simone, Clara, Di Lernia, Vito, Dini, Valentina, Donini, Massimo, Errichetti, Enzo, Esposito, Maria, Fargnoli, Maria Concetta, Foti, Antonio, Fiorella, Carmen, Gargiulo, Luigi, Gisondi, Paolo, Guarneri, Claudio, Legori, Agostina, Lembo, Serena, Loconsole, Francesco, Malagoli, Piergiorigio, Marzano, Angelo Valerio, Mercuri, Santo Raffaele, Megna, Matteo, Micali, Giuseppe, Mortato, Edoardo, Musumeci, Maria Letizia, Narcisi, Alessandra, Offidani, Anna Maria, Orsini, Diego, Paolino, Giovanni, Pellacani, Giovanni, Peris, Ketty, Potenza, Concetta, Prignano, Francesca, Quaglino, Pietro, Ribero, Simone, Richetta, Antonio Giovanni, Romanelli, Marco, Rossi, Antonio, Strippoli, Davide, Trovato, Emanuele, Venturini, Marina, Bianchi, Luca, Campione, E, Artosi, F, Shumak, R, Giunta, A, Argenziano, G, Assorgi, C, Balato, A, Bernardini, N, Brunasso, A, Burlando, M, Caldarola, G, Campanati, A, Carugno, A, Castelli, F, Conti, A, Costanzo, A, Cuccia, A, Dapavo, P, Dattola, A, De Simone, C, Di Lernia, V, Dini, V, Donini, M, Errichetti, E, Esposito, M, Fargnoli, M, Foti, A, Fiorella, C, Gargiulo, L, Gisondi, P, Guarneri, C, Legori, A, Lembo, S, Loconsole, F, Malagoli, P, Marzano, A, Mercuri, S, Megna, M, Micali, G, Mortato, E, Musumeci, M, Narcisi, A, Offidani, A, Orsini, D, Paolino, G, Pellacani, G, Peris, K, Potenza, C, Prignano, F, Quaglino, P, Ribero, S, Richetta, A, Romanelli, M, Rossi, A, Strippoli, D, Trovato, E, Venturini, M, Bianchi, L, Campione, Elena, Artosi, Fabio, Shumak, Ruslana Gaeta, Giunta, Alessandro, Argenziano, Giuseppe, Assorgi, Chiara, Balato, Anna, Bernardini, Nicoletta, Brunasso, Alexandra Maria Giovanna, Burlando, Martina, Caldarola, Giacomo, Campanati, Anna, Carugno, Andrea, Castelli, Franco, Conti, Andrea, Costanzo, Antonio, Cuccia, Aldo, Dapavo, Paolo, Dattola, Annunziata, De Simone, Clara, Di Lernia, Vito, Dini, Valentina, Donini, Massimo, Errichetti, Enzo, Esposito, Maria, Fargnoli, Maria Concetta, Foti, Antonio, Fiorella, Carmen, Gargiulo, Luigi, Gisondi, Paolo, Guarneri, Claudio, Legori, Agostina, Lembo, Serena, Loconsole, Francesco, Malagoli, Piergiorigio, Marzano, Angelo Valerio, Mercuri, Santo Raffaele, Megna, Matteo, Micali, Giuseppe, Mortato, Edoardo, Musumeci, Maria Letizia, Narcisi, Alessandra, Offidani, Anna Maria, Orsini, Diego, Paolino, Giovanni, Pellacani, Giovanni, Peris, Ketty, Potenza, Concetta, Prignano, Francesca, Quaglino, Pietro, Ribero, Simone, Richetta, Antonio Giovanni, Romanelli, Marco, Rossi, Antonio, Strippoli, Davide, Trovato, Emanuele, Venturini, Marina, and Bianchi, Luca

Abstract

(1) Background/Objectives: Nail psoriasis (NP) is a chronic and difficult-to-treat disease, which causes significant social stigma and impairs the patients’ quality of life. Moreover, nail psoriasis is a true therapeutic challenge for clinicians. The presence of nail psoriasis can be part of a severe form of psoriasis and can have predictive value for the development of psoriatic arthritis. Our real-world-evidence multicenter study aims to evaluate the efficacy of bimekizumab in nail psoriasis. (2) Methods: A retrospective analysis of a multicenter observational study included 834 patients affected by moderate-to-severe psoriasis, in 33 Dermatologic Units in Italy, treated with bimekizumab from December 2022 to September 2023. Clinimetric assessments were based on Psoriasis Area and Severity Index (PASI), Dermatology Life Quality Index (DLQI), and Physician’s Global Assessment of Fingernail Psoriasis (PGA-F) for the severity of nail psoriasis at 0, 12, 24, and 36 weeks. (3) Results: Psoriatic nail involvement was present in 27.95% of patients. The percentage of patients who achieved a complete clearance of NP in terms of PGA-F 0 was 31.7%, 57%, and 88.5% at week 4, 16, and 36, respectively. PASI 100 was achieved by 32.03% of patients at week 4, by 61.8% at week 16, and by 78.92% of patients at week 36. The mean baseline PASI was 16.24. The mean DLQI values for the entire group of patients at baseline, at week 4, at week 16, and at week 36 were 14.62, 3.02, 0.83, and 0.5, respectively. (4) Conclusions: Therapies that promote the healing of both the skin and nails in a short time can also ensure a lower risk of subsequently developing arthritis which is disabling over time. Bimekizumab proved to be particularly effective to treat NP, with a fast response in terms of complete clearance, with over 88.5% of patients free from NP after 36 weeks. The findings of our real-world study showed that patients with moderate-to-severe PsO and concomitant NP had significantly faste

Published
2024

12. Fast Clinical Response of Bimekizumab in Nail Psoriasis: A Retrospective Multicenter 36-Week Real-Life Study

Author

Campione, E., Artosi, F., Shumak, R. G., Giunta, A., Argenziano, G., Assorgi, C., Balato, A., Bernardini, N., Brunasso, A. M. G., Burlando, M., Caldarola, Giacomo, Campanati, A., Carugno, A., Castelli, F., Conti, A., Costanzo, A., Cuccia, A., Dapavo, P., Dattola, A., De Simone, Clara, Di Lernia, V., Dini, Veronica, Donini, Lorenzo Maria, Errichetti, E., Esposito, M., Fargnoli, Maria Concetta, Foti, A., Fiorella, C., Gargiulo, L., Gisondi, P., Guarneri, C., Legori, A., Lembo, S., Loconsole, F., Malagoli, P., Marzano, A. V., Mercuri, S. R., Megna, M., Micali, G., Mortato, E., Musumeci, M. L., Narcisi, A., Offidani, A. M., Orsini, D., Paolino, G., Pellacani, G., Peris, Ketty, Potenza, C., Prignano, F., Quaglino, P., Ribero, S., Richetta, A. G., Romanelli, Margherita, Rossi, A., Strippoli, D., Trovato, E., Venturini, M., Bianchi, L., Caldarola G. (ORCID:0000-0002-8837-9232), De Simone C. (ORCID:0000-0002-0898-0045), Dini V., Donini M., Fargnoli M. C., Peris K. (ORCID:0000-0002-5237-0463), Romanelli M., Campione, E., Artosi, F., Shumak, R. G., Giunta, A., Argenziano, G., Assorgi, C., Balato, A., Bernardini, N., Brunasso, A. M. G., Burlando, M., Caldarola, Giacomo, Campanati, A., Carugno, A., Castelli, F., Conti, A., Costanzo, A., Cuccia, A., Dapavo, P., Dattola, A., De Simone, Clara, Di Lernia, V., Dini, Veronica, Donini, Lorenzo Maria, Errichetti, E., Esposito, M., Fargnoli, Maria Concetta, Foti, A., Fiorella, C., Gargiulo, L., Gisondi, P., Guarneri, C., Legori, A., Lembo, S., Loconsole, F., Malagoli, P., Marzano, A. V., Mercuri, S. R., Megna, M., Micali, G., Mortato, E., Musumeci, M. L., Narcisi, A., Offidani, A. M., Orsini, D., Paolino, G., Pellacani, G., Peris, Ketty, Potenza, C., Prignano, F., Quaglino, P., Ribero, S., Richetta, A. G., Romanelli, Margherita, Rossi, A., Strippoli, D., Trovato, E., Venturini, M., Bianchi, L., Caldarola G. (ORCID:0000-0002-8837-9232), De Simone C. (ORCID:0000-0002-0898-0045), Dini V., Donini M., Fargnoli M. C., Peris K. (ORCID:0000-0002-5237-0463), and Romanelli M.

Abstract

(1) Background/Objectives: Nail psoriasis (NP) is a chronic and difficult-to-treat disease, which causes significant social stigma and impairs the patients’ quality of life. Moreover, nail psoriasis is a true therapeutic challenge for clinicians. The presence of nail psoriasis can be part of a severe form of psoriasis and can have predictive value for the development of psoriatic arthritis. Our real-world-evidence multicenter study aims to evaluate the efficacy of bimekizumab in nail psoriasis. (2) Methods: A retrospective analysis of a multicenter observational study included 834 patients affected by moderate-to-severe psoriasis, in 33 Dermatologic Units in Italy, treated with bimekizumab from December 2022 to September 2023. Clinimetric assessments were based on Psoriasis Area and Severity Index (PASI), Dermatology Life Quality Index (DLQI), and Physician’s Global Assessment of Fingernail Psoriasis (PGA-F) for the severity of nail psoriasis at 0, 12, 24, and 36 weeks. (3) Results: Psoriatic nail involvement was present in 27.95% of patients. The percentage of patients who achieved a complete clearance of NP in terms of PGA-F 0 was 31.7%, 57%, and 88.5% at week 4, 16, and 36, respectively. PASI 100 was achieved by 32.03% of patients at week 4, by 61.8% at week 16, and by 78.92% of patients at week 36. The mean baseline PASI was 16.24. The mean DLQI values for the entire group of patients at baseline, at week 4, at week 16, and at week 36 were 14.62, 3.02, 0.83, and 0.5, respectively. (4) Conclusions: Therapies that promote the healing of both the skin and nails in a short time can also ensure a lower risk of subsequently developing arthritis which is disabling over time. Bimekizumab proved to be particularly effective to treat NP, with a fast response in terms of complete clearance, with over 88.5% of patients free from NP after 36 weeks. The findings of our real-world study showed that patients with moderate-to-severe PsO and concomitant NP had significantly faste

Published
2024

13. Real-life effectiveness and safety of baricitinib in patients with severe alopecia areata: A 24-week Italian study

Author

Piraccini, B. M., Pampaloni, F., Cedirian, S., Quadrelli, F., Bruni, F., Rapparini, L., Caro, G., Acri, M. C., Ala, L., Rossi, A., Pellacani, G., Lacarrubba, F., Micali, G., Dall'Oglio, F., Vastarella, M., Cantelli, M., Nappa, P., Diluvio, L., Bianchi, L., Gnesotto, L., Sechi, A., Naldi, L., Tassone, F., Peris, Ketty, Caldarola, Giacomo, Pinto, Lorenzo Maria, Girolomoni, G., Marangoni, F., Bellinato, F., Gisondi, P., Scandagli, I., Prignano, F., Pimpinelli, N., Tomasini, C., Barruscotti, S., Desimoni, E., Simonetti, O., Ambrogio, F., Foti, C., Boccaletti, V., Fraghi, A., Marzano, A. V., Mattioli, M. A., Rocca, Lorenzo, Barbareschi, M., Ferrucci, S. M., Gallo, G., Ribero, S., Quaglino, P., Balestri, R., Ioris, T., Caposienacaro, R. D., Zalaudek, Iri, Vagnozzi, E., Fargnoli, Maria Concetta, Caponio, C., Rubegni, P., Cinotti, E., Trovato, E., Romanelli, Margherita, Dini, Veronica, Manzomargiotta, F., Feliciani, C., de FelicidelGiudice, M. B., Atzori, L., Sanna, S., Lembo, S., Raimondo, A., Magnano, M., Starace, M., Peris K. (ORCID:0000-0002-5237-0463), Caldarola G. (ORCID:0000-0002-8837-9232), Pinto L. M., Rocca L., Zalaudek I., Fargnoli M. C., Romanelli M., Dini V., Piraccini, B. M., Pampaloni, F., Cedirian, S., Quadrelli, F., Bruni, F., Rapparini, L., Caro, G., Acri, M. C., Ala, L., Rossi, A., Pellacani, G., Lacarrubba, F., Micali, G., Dall'Oglio, F., Vastarella, M., Cantelli, M., Nappa, P., Diluvio, L., Bianchi, L., Gnesotto, L., Sechi, A., Naldi, L., Tassone, F., Peris, Ketty, Caldarola, Giacomo, Pinto, Lorenzo Maria, Girolomoni, G., Marangoni, F., Bellinato, F., Gisondi, P., Scandagli, I., Prignano, F., Pimpinelli, N., Tomasini, C., Barruscotti, S., Desimoni, E., Simonetti, O., Ambrogio, F., Foti, C., Boccaletti, V., Fraghi, A., Marzano, A. V., Mattioli, M. A., Rocca, Lorenzo, Barbareschi, M., Ferrucci, S. M., Gallo, G., Ribero, S., Quaglino, P., Balestri, R., Ioris, T., Caposienacaro, R. D., Zalaudek, Iri, Vagnozzi, E., Fargnoli, Maria Concetta, Caponio, C., Rubegni, P., Cinotti, E., Trovato, E., Romanelli, Margherita, Dini, Veronica, Manzomargiotta, F., Feliciani, C., de FelicidelGiudice, M. B., Atzori, L., Sanna, S., Lembo, S., Raimondo, A., Magnano, M., Starace, M., Peris K. (ORCID:0000-0002-5237-0463), Caldarola G. (ORCID:0000-0002-8837-9232), Pinto L. M., Rocca L., Zalaudek I., Fargnoli M. C., Romanelli M., and Dini V.

Abstract

Background: Alopecia areata is an autoimmune condition characterized by rapid hair loss in the scalp, eyebrows and eyelashes, for which treatments are limited. Baricitinib, an oral inhibitor of Janus kinases 1 and 2, has been recently approved to treat alopecia areata. Materials and Methods: We conducted a retrospective study involving 23 medical centres across Italy, enrolling patients affected by severe alopecia areata (SALT >50), for more than 6 months. Clinical and trichoscopic assessment was performed at each visit and impact on quality of life, anxiety and depression were evaluated using the Skindex-16 and the Hospital Anxiety and Depression Scale (HADS), respectively. Results: A total of 118 patients were enrolled, with a mean age of 39 years and a mean SALT >95. The mean value of the SALT score decreased from an average of 96.6 (±8.23 sd) to 48 (±35.2 sd) after 24 weeks of treatment and 42.3% of patients achieved a SALT 30, 31.3% a SALT 20 and 20.3% a SALT 10 by Week 24. Trichoscopic signs showed fewer yellow dots and black dots significantly earlier than hair regrowth. Adverse events during the treatment period (mild laboratory test abnormalities) were reported in 12.7% patients. No drop-out were registered. Conclusion: Data on the effectiveness and safety of baricitinib are promising and support the use of this drug in severe forms of AA, also in the early stages. We also suggest performing trichoscopy in order to reveal early response to therapy.

Published
2024

14. Efficacy and tolerability of tirbanibulin 1% ointment in the treatment of cancerization field: a real-life Italian multicenter observational study of 250 patients

Author

Nazzaro, G, Carugno, A, Bortoluzzi, P, Buffon, S, Astrua, C, Zappia, E, Trovato, E, Caccavale, S, Pellegrino, V, Paolino, G, Balestri, R, Lacava, R, Ciccarese, G, Verdelli, A, Barruscotti, S, Valenti, M, Toni, G, Giacalone, S, Zavattaro, E, Gironi, L, Mercuri, S, Ribero, S, Gisondi, P, Sena, P, Marzano, A, Gironi, LC, Mercuri, SR, Marzano, AV, Nazzaro, G, Carugno, A, Bortoluzzi, P, Buffon, S, Astrua, C, Zappia, E, Trovato, E, Caccavale, S, Pellegrino, V, Paolino, G, Balestri, R, Lacava, R, Ciccarese, G, Verdelli, A, Barruscotti, S, Valenti, M, Toni, G, Giacalone, S, Zavattaro, E, Gironi, L, Mercuri, S, Ribero, S, Gisondi, P, Sena, P, Marzano, A, Gironi, LC, Mercuri, SR, and Marzano, AV

Abstract

Background: Tirbanibulin 1% ointment is approved for the field treatment of Olsen grade I actinic keratoses (AKs) of the face and scalp. Methods: We performed a multicenter retrospective study involving 15 dermatologic units in Italy to investigate the efficacy and tolerability of tirbanibulin in a real-life setting. 250 patients were enrolled. Tirbanibulin, 1% ointment, was applied daily for five consecutive days. The efficacy of treatment was measured with modifications of the Actinic Keratosis Area and Severity Index (AKASI). A satisfactory response was defined by complete (100% reduction in the number of lesions) or partial clearance (75-99%) of treated AKs. Results: Overall, the AKASI score was significantly reduced in the studied population (mean, from 4.1 ± 2.7 to 1.4 ± 1.5; P < 0.001). A satisfactory response was observed in 222 (88.8%) cases. The proportion of satisfactory responses was higher when follow-up was performed after 8 weeks (34/35, 97.1%). The reduction in AKASI was significant in patients with Olsen grade II or III lesions (from 5.3 ± 2.8 to 1.6 ± 1.6; P < 0.001). A satisfactory response was observed in 91/104 (87.5%) cases. AKASI reduction was also significant in patients with trunk or limb AKs (from 7.0 ± 1.3 to 2.0 ± 1.6; P = 0.018) since a satisfactory response was observed in 7/8 (87.5%) cases. Tirbanibulin was well tolerated; all adverse events (AEs) included transient local reactions at the site of treatment. Overall, 231 patients had at least one AE. Only 7 (2.8%) grade 4 AEs were recorded. Conclusion: Our retrospective study confirmed that tirbanibulin 1% ointment is effective and well tolerated in a real-life setting and is also promising for Olsen grade II and grade III AKs and AKs localized on difficult-to-treat areas.

Published
2024

15. Comparative effectiveness of tildrakizumab 200 mg versus tildrakizumab 100 mg in psoriatic patients with high disease burden or above 90 kg of body weight: a 16-week multicenter retrospective study - IL PSO (Italian landscape psoriasis)

Author

Gargiulo, L, Ibba, L, Cascio Ingurgio, R, Malagoli, P, Amoruso, F, Balato, A, Bardazzi, F, Brianti, P, Brunasso, G, Burlando, M, Cagni, A, Caproni, M, Carrera, C, Carugno, A, Caudullo, F, Cuccia, A, Dapavo, P, Di Brizzi, E, Dini, V, Gaiani, F, Gisondi, P, Guarneri, C, Lasagni, C, Licata, G, Loconsole, F, Marzano, A, Megna, M, Mercuri, S, Musumeci, M, Orsini, D, Ribero, S, Ruffo Di Calabria, V, Satolli, F, Strippoli, D, Travaglini, M, Trovato, E, Venturini, M, Zichichi, L, Valenti, M, Costanzo, A, Narcisi, A, Gargiulo, Luigi, Ibba, Luciano, Cascio Ingurgio, Ruggero, Malagoli, Piergiorgio, Amoruso, Fabrizio, Balato, Anna, Bardazzi, Federico, Brianti, Pina, Brunasso, Giovanna, Burlando, Martina, Cagni, Anna E, Caproni, Marzia, Carrera, Carlo G, Carugno, Andrea, Caudullo, Francesco, Cuccia, Aldo, Dapavo, Paolo, Di Brizzi, Eugenia V, Dini, Valentina, Gaiani, Francesca M, Gisondi, Paolo, Guarneri, Claudio, Lasagni, Claudia, Licata, Gaetano, Loconsole, Francesco, Marzano, Angelo V, Megna, Matteo, Mercuri, Santo R, Musumeci, Maria L, Orsini, Diego, Ribero, Simone, Ruffo Di Calabria, Valentina, Satolli, Francesca, Strippoli, Davide, Travaglini, Massimo, Trovato, Emanuele, Venturini, Marina, Zichichi, Leonardo, Valenti, Mario, Costanzo, Antonio, Narcisi, Alessandra, Gargiulo, L, Ibba, L, Cascio Ingurgio, R, Malagoli, P, Amoruso, F, Balato, A, Bardazzi, F, Brianti, P, Brunasso, G, Burlando, M, Cagni, A, Caproni, M, Carrera, C, Carugno, A, Caudullo, F, Cuccia, A, Dapavo, P, Di Brizzi, E, Dini, V, Gaiani, F, Gisondi, P, Guarneri, C, Lasagni, C, Licata, G, Loconsole, F, Marzano, A, Megna, M, Mercuri, S, Musumeci, M, Orsini, D, Ribero, S, Ruffo Di Calabria, V, Satolli, F, Strippoli, D, Travaglini, M, Trovato, E, Venturini, M, Zichichi, L, Valenti, M, Costanzo, A, Narcisi, A, Gargiulo, Luigi, Ibba, Luciano, Cascio Ingurgio, Ruggero, Malagoli, Piergiorgio, Amoruso, Fabrizio, Balato, Anna, Bardazzi, Federico, Brianti, Pina, Brunasso, Giovanna, Burlando, Martina, Cagni, Anna E, Caproni, Marzia, Carrera, Carlo G, Carugno, Andrea, Caudullo, Francesco, Cuccia, Aldo, Dapavo, Paolo, Di Brizzi, Eugenia V, Dini, Valentina, Gaiani, Francesca M, Gisondi, Paolo, Guarneri, Claudio, Lasagni, Claudia, Licata, Gaetano, Loconsole, Francesco, Marzano, Angelo V, Megna, Matteo, Mercuri, Santo R, Musumeci, Maria L, Orsini, Diego, Ribero, Simone, Ruffo Di Calabria, Valentina, Satolli, Francesca, Strippoli, Davide, Travaglini, Massimo, Trovato, Emanuele, Venturini, Marina, Zichichi, Leonardo, Valenti, Mario, Costanzo, Antonio, and Narcisi, Alessandra

Abstract

Purpose: Tildrakizumab is a selective inhibitor of IL-23 approved for the treatment of moderate-to-severe plaque psoriasis in two dosages. We conducted a 16-week multicenter retrospective study to compare the effectiveness and safety of tildrakizumab 200 mg versus tildrakizumab 100 mg in patients with a high disease burden or high body weight. Materials and methods: Our retrospective study included 134 patients treated with tildrakizumab 200 mg and 364 patients treated with tildrakizumab 100 mg from 28 Italian Dermatology Units affected by moderate-to-severe plaque psoriasis. The patients had a body weight above 90 kg or a high disease burden (Psoriasis Area and Severity Index [PASI] ≥ 16 or the involvement of difficult-to-treat areas). We evaluated the effectiveness of tildrakizumab at the week-16 visit in terms of PASI90, PASI100 and absolute PASI ≤ 2. Results: After 16 weeks of treatment with tildrakizumab 200 mg, PASI90 was reached by 57.5% of patients and PASI100 by 39.6% of patients. At the same time point, 34.3% and 24.2% of patients treated with tildrakizumab 100 mg achieved PASI90 and PASI100, respectively. Conclusions: Our data suggest that tildrakizumab 200 mg has better effectiveness than tildrakizumab 100 mg in patients with a body weight ≥ 90 kg and a high disease burden.

Published
2024

19. Predictors of recurrence and progression in poorly differentiated cutaneous squamous cell carcinomas: insights from a real-life experience

Author

Roccuzzo, G., primary, Orlando, G., additional, Rumore, M.R., additional, Morrone, A., additional, Fruttero, E., additional, Caliendo, V., additional, Picciotto, F., additional, Sciarrillo, A., additional, Quaglino, P., additional, Cassoni, P., additional, Ribero, S., additional, and Senetta, R., additional

Published
2024
Full Text
View/download PDF

21. More than one shade of pink as a marker of early amelanotic/hypomelanotic melanoma.

Author

Pizzichetta, M. A., Corsetti, P., Stanganelli, I., Ghigliotti, G., Cavicchini, S., De Giorgi, V., Bono, R., Astorino, S., Ribero, S., Argenziano, G., Alaibac, and Polesel, J.

Abstract

Amelanotic/hypomelanotic melanoma (AHM) may be difficult to diagnose because of a lack of pigmentation. To evaluate whether dermoscopy can be useful for the diagnosis of early AHM, 133 digital dermoscopic images of lesions histopathologically diagnosed as amelanotic/hypomelanotic superficial spreading melanoma with ≤1 mm thickness (AHSSMs) (n = 27), amelanotic/hypomelanotic non‐melanocytic lesions (AHNMLs) (e.g., seborrhoeic keratosis and basal cell carcinoma) (n = 79), and amelanotic/hypomelanotic benign melanocytic lesions (AHBMLs) (e.g., compound and dermal nevi) (n = 27), were dermoscopically assessed by three blinded dermatologists. Using multivariate analysis, we found a significantly increased risk of diagnosing AHSSM versus AHNML and AHBML when the lesion was characterized by the presence of more than one shade of pink (odds ratio [OR] 37.11), irregular dots/globules (OR 23.73), asymmetric pigmentation (OR 8.85), and structureless pattern (OR 7.33). In conclusion, dermoscopy may improve early AHM detection, discriminating AHSSM from amelanotic/hypomelanotic non melanoma lesions. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

27. Global patterns of care in advanced stage mycosis fungoides/Sezary syndrome: a multicenter retrospective follow-up study from the Cutaneous Lymphoma International Consortium

Author

Quaglino, P., Maule, M., Prince, H.M., Porcu, P., Horwitz, S., Duvic, M., Talpur, R., Vermeer, M., Bagot, M., Guitart, J., Papadavid, E., Sanches, J.A., Hodak, E., Sugaya, M., Berti, E., Ortiz-Romero, P., Pimpinelli, N., Servitje, O., Pileri, A., Zinzani, P.L., Estrach, T., Knobler, R., Stadler, R., Fierro, M.T., Alberti Violetti, S., Amitay-Laish, I., Antoniou, C., Astrua, C., Chaganti, S., Child, F., Combalia, A., Fabbro, S., Fava, P., Grandi, V., Jonak, C., Martinez-Escala, E., Kheterpal, M., Kim, E.J., McCormack, C., Miyagaki, T., Miyashiro, D., Morris, S., Muniesa, C., Nikolaou, V., Ognibene, G., Onida, F., Osella-Abate, S., Porkert, S., Postigo-Llorente, C., Ram-Wolff, C., Ribero, S., Rogers, K., Sanlorenzo, M., Stranzenbach, R., Spaccarelli, N., Stevens, A., Zugna, D., Rook, A.H., Geskin, L.J., Willemze, R., Whittaker, S., Hoppe, R., Scarisbrick, J., and Kim, Y.

Published
2017
Full Text
View/download PDF

29. Drug survival, effectiveness and safety of ixekizumab for moderate‐to‐severe psoriasis up to 5 years.

Author

Mastorino, L., Dapavo, P., Burzi, L., Rosset, F., Giunipero di Corteranzo, I., Leo, F., Verrone, A., Stroppiana, E., Ortoncelli, M., Ribero, S., and Quaglino, P.

Subjects
PSORIATIC arthritis, PSORIASIS, CLINICAL trials, LOGISTIC regression analysis
Abstract

Introduction: Ixekizumab proved to be effective and safe for psoriasis treatment in several randomized clinical trials and real‐life studies. Nevertheless, long‐term real‐world experiences are still lacking, with little data up to 4 years of treatment. Objectives: To analyse survival, effectiveness and safety of ixekizumab in a real‐life cohort of patients affected by moderate‐to‐severe psoriasis or psoriatic arthritis up to 260 weeks (5 years). Methods: We included all patients treated with ixekizumab from December 2017 to March 2021. Drug survival (DS) was analysed in patients at risk for up to 5 years. Cox analysis was adopted to evaluate possible predictive factors of discontinuation. Psoriasis Area Severity Index (meanPASI and PASI100, 90, and ≤3) was used as outcomes of effectiveness on observed patients at 16, 52, 104, 156, 208 and 260 weeks. Logistic regression was performed to identify possible predictive factors of response. Results: DS was 65.5% at 260 weeks, with being a super‐responder patient (achievement of PASI100 at 16 weeks and maintained at 28 weeks) correlated with less risk of discontinuation. PASI100, 90 and ≤3 was achieved by 54.1%, 60.5% and 73% of observed patients, respectively, at 16 weeks, and by 59.1%, 81.8% and 95.5%, respectively, at 260 weeks. High mean BMI was the only factor strongly associated with less achievement of the outcomes at the earlier time points: PASI100 at 16 weeks (OR 0.93, CI 0.87–0.98, p = 0.014) and at 104 weeks (OR 0.91, CI 0.84–0.98, p = 0.019), PASI90 achievement at 16 weeks (OR 0.94, CI 0.88–0.99, p = 0.028) and 104 weeks (OR 0.91, CI 0.83–0.99, p = 0.027), and PASI ≤3 (OR 0.86, CI 0.76–0.97, p = 0.018) at 104 weeks. No severe adverse events were observed. Conclusions: Ixekizumab showed high effectiveness and safety for up to 5 years, with survival of 2/3 of treated patients. Rapid response to treatment is predictive of long‐term response. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

32. Long-term proactive management of psoriasis with calcipotriol and betamethasone dipropionate foam: an Italian consensus through a combined nominal group technique and Delphi approach

Author

De Simone, C, Dapavo, P, Malagoli, P, Martella, A, Campanati, A, Campione, E, Errichetti, E, Franchi, C, Gambardella, A, Megna, M, Osti, F, Ribero, S, Zagni, G, Calzavara-Pinton, P, Fabbrocini, G, Amoruso, G, Baglieri, F, Biamonte, A, Bianchelli, T, Bigi, L, Bortoli, J, Brunetti, B, Buligan, C, Cagni, E, Calderoni, O, Caputo, A, Carrera, C, Carugno, A, Chersi, K, Cicchelli, S, De Natale, F, Di Maria, D, Ferrari, A, Fogli, E, Forconi, R, Galeazzi, A, Giovannini, A, Giura, M, Iuculano, M, Lazzaretti, G, Leporati, C, Magnanini, M, Marconi, B, Maruccia, A, Miglietta, R, Minuti, A, Mocci, L, Modica, S, Narcisi, A, Odorici, G, Pazzaglia, M, Peila, R, Pertusi, G, Pezza, M, Pezzullo, E, Puccia, N, Raulo, U, Rossi, M, Rusignuolo, S, Sapienza, G, Savarese, C, Scalisi, M, Strippoli, D, Stroppiana, E, Tiberio, R, Trischitta, A, Tucci, M, Vaira, F, Verrone, A, Villa, L, Zagni, F, Zoccali, A, De Simone C., Dapavo P., Malagoli P., Martella A., Campanati A., Campione E., Errichetti E., Franchi C., Gambardella A., Megna M., Osti F., Ribero S., Zagni G., Calzavara-Pinton P., Fabbrocini G., Amoruso G. F., Baglieri F., Biamonte A. S., Bianchelli T., Bigi L., Bortoli J., Brunetti B., Buligan C., Cagni E., Calderoni O., Caputo A., Carrera C. G., Carugno A., Chersi K., Cicchelli S., De Natale F., Di Maria D., Ferrari A. S., Fogli E., Forconi R., Galeazzi A., Giovannini A., Giura M. T., Iuculano M., Lazzaretti G., Leporati C., Magnanini M., Marconi B., Maruccia A., Miglietta R., Minuti A., Mocci L., Modica S., Narcisi A., Odorici G., Pazzaglia M., Peila R., Pertusi G., Pezza M., Pezzullo E., Puccia N., Raulo U., Rossi M., Rusignuolo S., Sapienza G., Savarese C., Scalisi M., Strippoli D., Stroppiana E., Tiberio R., Trischitta A., Tucci M. G., Vaira F., Verrone A., Villa L., Zagni F., Zoccali A., De Simone, C, Dapavo, P, Malagoli, P, Martella, A, Campanati, A, Campione, E, Errichetti, E, Franchi, C, Gambardella, A, Megna, M, Osti, F, Ribero, S, Zagni, G, Calzavara-Pinton, P, Fabbrocini, G, Amoruso, G, Baglieri, F, Biamonte, A, Bianchelli, T, Bigi, L, Bortoli, J, Brunetti, B, Buligan, C, Cagni, E, Calderoni, O, Caputo, A, Carrera, C, Carugno, A, Chersi, K, Cicchelli, S, De Natale, F, Di Maria, D, Ferrari, A, Fogli, E, Forconi, R, Galeazzi, A, Giovannini, A, Giura, M, Iuculano, M, Lazzaretti, G, Leporati, C, Magnanini, M, Marconi, B, Maruccia, A, Miglietta, R, Minuti, A, Mocci, L, Modica, S, Narcisi, A, Odorici, G, Pazzaglia, M, Peila, R, Pertusi, G, Pezza, M, Pezzullo, E, Puccia, N, Raulo, U, Rossi, M, Rusignuolo, S, Sapienza, G, Savarese, C, Scalisi, M, Strippoli, D, Stroppiana, E, Tiberio, R, Trischitta, A, Tucci, M, Vaira, F, Verrone, A, Villa, L, Zagni, F, Zoccali, A, De Simone C., Dapavo P., Malagoli P., Martella A., Campanati A., Campione E., Errichetti E., Franchi C., Gambardella A., Megna M., Osti F., Ribero S., Zagni G., Calzavara-Pinton P., Fabbrocini G., Amoruso G. F., Baglieri F., Biamonte A. S., Bianchelli T., Bigi L., Bortoli J., Brunetti B., Buligan C., Cagni E., Calderoni O., Caputo A., Carrera C. G., Carugno A., Chersi K., Cicchelli S., De Natale F., Di Maria D., Ferrari A. S., Fogli E., Forconi R., Galeazzi A., Giovannini A., Giura M. T., Iuculano M., Lazzaretti G., Leporati C., Magnanini M., Marconi B., Maruccia A., Miglietta R., Minuti A., Mocci L., Modica S., Narcisi A., Odorici G., Pazzaglia M., Peila R., Pertusi G., Pezza M., Pezzullo E., Puccia N., Raulo U., Rossi M., Rusignuolo S., Sapienza G., Savarese C., Scalisi M., Strippoli D., Stroppiana E., Tiberio R., Trischitta A., Tucci M. G., Vaira F., Verrone A., Villa L., Zagni F., and Zoccali A.

Abstract

Background: Although long-term management of psoriasis is paramount, this approach is challenging in clinical practice. In the recent PSO-LONG trial, a fixed-dose combination of betamethasone dipropionate (BD) and calcipotriol (Cal) foam applied twice a week on non-consecutive days for 52 weeks (proactive treatment) reduced the risk of relapse. However, the role of Cal/BD foam in the long-term management of psoriasis needs further clarifications. The ProActive Management (PAM) program, a nationwide Italian project, aims at reaching a consensus on the role of proactive management of psoriasis. Methods: A steering committee generated some statements through the nominal group technique (NGT). The statements were voted by an expert panel in an adapted Delphi voting process. Results: Eighteen statements were proposed, and the majority of them (14/18) reached a consensus during the Delphi voting. The need to provide long-term proactive topical treatment to reduce the risk of relapse for the treatment of challenging diseases sites or in patients where phototherapy or systemic therapies are contraindicated/ineffective was widely recognized. A consensus was reached about the possibility to associate the proactive treatment with systemic and biological therapies, without the need for dose intensification, thus favoring a prolonged remission. Moreover, the proactive treatment was recognized as more effective than weekend therapy in increasing time free from relapses. Approaches to improve adherence, on the other hand, need further investigation. Conclusions: The inclusion in guidelines of a proactive strategy among the effective treatment options will be a fundamental step in the evolution of a mild-moderate psoriasis therapeutic approach.

Published
2022

33. Monkeypox: an Italian, multicenter study of 104 cases

Author

Maronese, C, Ramoni, S, Avallone, G, Giacalone, S, Quattri, E, Gaspari, V, Rapparini, L, Robuffo, S, Delmonte, S, Merli, M, Tutone, M, Facci, G, Carugno, A, Parietti, M, Latini, A, Giuliani, E, Sena, P, Ribero, S, Quaglino, P, Piraccini, B, Marzano, A, Maronese, Carlo Alberto, Ramoni, Stefano, Avallone, Gianluca, Giacalone, Serena, Quattri, Eleonora, Gaspari, Valeria, Rapparini, Luca, Robuffo, Silvia, Delmonte, Sergio, Merli, Martina, Tutone, Marco, Facci, Giulia, Carugno, Andrea, Parietti, Michele, Latini, Alessandra, Giuliani, Eugenia, Sena, Paolo, Ribero, Simone, Quaglino, Pietro, Piraccini, Bianca Maria, Marzano, Angelo Valerio, Maronese, C, Ramoni, S, Avallone, G, Giacalone, S, Quattri, E, Gaspari, V, Rapparini, L, Robuffo, S, Delmonte, S, Merli, M, Tutone, M, Facci, G, Carugno, A, Parietti, M, Latini, A, Giuliani, E, Sena, P, Ribero, S, Quaglino, P, Piraccini, B, Marzano, A, Maronese, Carlo Alberto, Ramoni, Stefano, Avallone, Gianluca, Giacalone, Serena, Quattri, Eleonora, Gaspari, Valeria, Rapparini, Luca, Robuffo, Silvia, Delmonte, Sergio, Merli, Martina, Tutone, Marco, Facci, Giulia, Carugno, Andrea, Parietti, Michele, Latini, Alessandra, Giuliani, Eugenia, Sena, Paolo, Ribero, Simone, Quaglino, Pietro, Piraccini, Bianca Maria, and Marzano, Angelo Valerio

Published
2023

34. Melanocytic Lesions with Peripheral Globules: Proposal of an Integrated Management Algorithm

Author

Cappilli, Simone, Ribero, S., Cornacchia, L., Catapano, S., Del Regno, L., Quattrini, Laura, D'Amore, Antonio, Federico, Francesco, Broganelli, P., Peris, Ketty, Di Stefani, Alessandro, Cappilli S., Quattrini L., D'Amore A., Federico F. (ORCID:0000-0002-3077-1813), Peris K. (ORCID:0000-0002-5237-0463), Di Stefani A., Cappilli, Simone, Ribero, S., Cornacchia, L., Catapano, S., Del Regno, L., Quattrini, Laura, D'Amore, Antonio, Federico, Francesco, Broganelli, P., Peris, Ketty, Di Stefani, Alessandro, Cappilli S., Quattrini L., D'Amore A., Federico F. (ORCID:0000-0002-3077-1813), Peris K. (ORCID:0000-0002-5237-0463), and Di Stefani A.

Abstract

Introduction: A peripheral rim of globules represents a marker of the horizontal growth phase in ABSTRACT nevi and is a common feature in children and adolescents. The observation of melanocytic lesions with peripheral globules (MLPGs) in adulthood deserves more attention, since melanoma may exhibit this feature, albeit rarely. Risk-stratified management recommendations considering a global clinical approach are still missing. Objectives: To analyze current knowledge on MLPGs and propose an integrated management algorithm stratified for age groups. Methods: We conducted a narrative review of current published data on MLPGs, analyzing clinical dermoscopic and confocal distinguishing features of melanoma from benign nevi. Results: The risk of finding a melanoma when removing an MLPG increases with age, especially in people >55 years old, and is significantly higher in the extremities, head/neck and in case of a single asymmetrical lesion, ≥6 mm in diameter. Dermoscopic features associated with melanoma diagnosis include atypical peripheral globules, asymmetrical distribution, multiple rims as well as the reappearance of globules after prior loss. In addition, wide blue-grey regression areas, atypical networks, eccentric blotches, tan structureless peripheral areas and vascularization are atypical dermoscopic features. Confocal worrisome findings are represented by pagetoid cells within the epidermis, architectural disarrangement and atypical cells of the dermo-epidermal junction with irregular peripheral nests. Conclusion: We proposed a multi-step age-stratified management algorithm integrating clinical, dermoscopic and confocal findings that may increase the early recognition of melanoma and avoid surgical excision of benign nevi.

Published
2023

35. Long-term Effectiveness and Safety of Upadacitinib for Atopic Dermatitis in a Real-world Setting: An Interim Analysis Through 48 Weeks of Observation

Author

Chiricozzi, Andrea, Ortoncelli, M., Schena, D., Gori, Niccolo', Ferrucci, S. M., Babino, G., Napolitano, M., Fargnoli, Maria Concetta, Stingeni, L., Rossi, M., Romanelli, Margherita, Balestri, R., Pellegrino, M., Parodi, A., Bertoldi, A. M., Palazzo, G., Antonelli, Flaminia, Pitino, A., Tripepi, G., Fabbrocini, G., Balato, A., Marzano, A. V., Girolomoni, G., Ribero, S., Peris, Ketty, Chiricozzi A. (ORCID:0000-0002-6739-0387), Gori N., Fargnoli M. C., Romanelli M., Antonelli F., Peris K. (ORCID:0000-0002-5237-0463), Chiricozzi, Andrea, Ortoncelli, M., Schena, D., Gori, Niccolo', Ferrucci, S. M., Babino, G., Napolitano, M., Fargnoli, Maria Concetta, Stingeni, L., Rossi, M., Romanelli, Margherita, Balestri, R., Pellegrino, M., Parodi, A., Bertoldi, A. M., Palazzo, G., Antonelli, Flaminia, Pitino, A., Tripepi, G., Fabbrocini, G., Balato, A., Marzano, A. V., Girolomoni, G., Ribero, S., Peris, Ketty, Chiricozzi A. (ORCID:0000-0002-6739-0387), Gori N., Fargnoli M. C., Romanelli M., Antonelli F., and Peris K. (ORCID:0000-0002-5237-0463)

Abstract

Background: Janus kinase (JAK) inhibitors, including upadacitinib, have been recently approved for the treatment of moderate-severe atopic dermatitis (AD) and real-world data on upadacitinib effectiveness and safety are limited. This interim analysis aimed to assess effectiveness and safety of upadacitinib throughout 48 weeks of observation in a real-world adult AD population. Methods: This prospective study collected data on adult patients affected by moderate-to-severe AD and treated with upadacitinib at the dosage of either 15 mg or 30 mg daily based on the physician decision. Upadacitinib was prescribed in the context of a national compassionate use programme. In this interim analysis, within patient comparisons of continuous scores of different scales (namely Eczema Area and Severity Index [EASI], body surface area [BSA], Dermatology Life Quality Index [DLQI], Patient Oriented Eczema Measure [POEM], Numeric Rating Scale [NRS] subtests) were performed. The percentage of patients achieving EASI 75, EASI 90 and EASI 100 at Week 16, 32 and 48 was also evaluated. Results: One hundred and forty-six patients were included in the analysis. Upadacitinib 15 mg or 30 mg daily was prescribed as monotherapy in most cases (127/146, 87.0%). Upadacitinib was initially prescribed at the dosage of 30 mg daily in 118 of 146 (80.8%) patients and 15 mg daily in 28/146 (19.2%) patients. A significant improvement in the clinical signs and symptoms of AD was detected by Week 16 and throughout the study period. EASI 75, EASI 90 and EASI 100 responses were achieved by 87.6%, 69.1% and 44.3% at Week 48, associated with a sustained reduction in the mean values of all physician-reported (EASI and BSA) and patient-reported (Itch- Sleep- and Pain-NRS, DLQI, and POEM) disease severity outcomes, up to 48 weeks of treatment. Treatment response observed in 15 mg upadacitinib-treated patients was comparable with that detected in 30 mg upadacitinib-treated patients, revealing no statisti

Published
2023

36. A 52-week update of a multicentre Italian real-world experience on effectiveness and safety of dupilumab in adolescents with moderate-to-severe atopic dermatitis

Author

Stingeni, L., Bianchi, L., Antonelli, E., Caroppo, E. S., Ferrucci, S. M., Gurioli, C., Ortoncelli, M., Fabbrocini, G., Nettis, E., Schena, D., Napolitano, M., Gola, M., Bonzano, L., Rossi, M., Belloni Fortina, A., Balato, A., Peris, Ketty, Foti, C., Guarneri, F., Romanelli, M., Patruno, C., Savoia, P., Esposito, M., Russo, F., Errichetti, E., Bianchelli, T., Pellacani, G., Feliciani, C., Offidani, A., Corazza, M., Micali, G., Milanesi, N., Malara, G., Chiricozzi, Andrea, Tramontana, M., Hansel, K., Buligan, C., Caroppo, F., Bello, G. D., Dastoli, S., Di Brizzi, E. V., Del Giudice, M. B. D. F., Diluvio, L., Fargnoli, Maria Concetta, Gelmetti, A., Giacchetti, A., Grieco, T., Iannone, M., Macchia, L., Marietti, R., Musumeci, M. L., Motolese, A., Neri, I., Radi, G., Ribero, S., Romita, P., Tavecchio, S., Tronconi, G., Veronese, F., Peris K. (ORCID:0000-0002-5237-0463), Chiricozzi A. (ORCID:0000-0002-6739-0387), Fargnoli M. C., Stingeni, L., Bianchi, L., Antonelli, E., Caroppo, E. S., Ferrucci, S. M., Gurioli, C., Ortoncelli, M., Fabbrocini, G., Nettis, E., Schena, D., Napolitano, M., Gola, M., Bonzano, L., Rossi, M., Belloni Fortina, A., Balato, A., Peris, Ketty, Foti, C., Guarneri, F., Romanelli, M., Patruno, C., Savoia, P., Esposito, M., Russo, F., Errichetti, E., Bianchelli, T., Pellacani, G., Feliciani, C., Offidani, A., Corazza, M., Micali, G., Milanesi, N., Malara, G., Chiricozzi, Andrea, Tramontana, M., Hansel, K., Buligan, C., Caroppo, F., Bello, G. D., Dastoli, S., Di Brizzi, E. V., Del Giudice, M. B. D. F., Diluvio, L., Fargnoli, Maria Concetta, Gelmetti, A., Giacchetti, A., Grieco, T., Iannone, M., Macchia, L., Marietti, R., Musumeci, M. L., Motolese, A., Neri, I., Radi, G., Ribero, S., Romita, P., Tavecchio, S., Tronconi, G., Veronese, F., Peris K. (ORCID:0000-0002-5237-0463), Chiricozzi A. (ORCID:0000-0002-6739-0387), and Fargnoli M. C.

Abstract

na

Published
2023

37. Current treatment goals are achieved by the majority of patients with atopic dermatitis treated with tralokinumab: results from a multicentric, multinational, retrospective, cohort study

Author

Chiricozzi, Andrea, Ferrucci, S. M., Di Nardo, Lucia, Gori, Niccolo', Balato, A., Ortoncelli, M., Maurelli, M., Galluzzo, M., Munera Campos, M., Seremet, T., Caldarola, Giacomo, De Simone, Clara, Ippoliti, Elena, Torres, T., Gkalpakiotis, S., Conrad, C., Carrascosa, J. M., Bianchi, L., Argenziano, G., Ribero, S., Girolomoni, G., Marzano, A. V., Peris, Ketty, Chiricozzi A. (ORCID:0000-0002-6739-0387), Di Nardo L., Gori N., Caldarola G. (ORCID:0000-0002-8837-9232), De Simone C. (ORCID:0000-0002-0898-0045), Ippoliti E., Peris K. (ORCID:0000-0002-5237-0463), Chiricozzi, Andrea, Ferrucci, S. M., Di Nardo, Lucia, Gori, Niccolo', Balato, A., Ortoncelli, M., Maurelli, M., Galluzzo, M., Munera Campos, M., Seremet, T., Caldarola, Giacomo, De Simone, Clara, Ippoliti, Elena, Torres, T., Gkalpakiotis, S., Conrad, C., Carrascosa, J. M., Bianchi, L., Argenziano, G., Ribero, S., Girolomoni, G., Marzano, A. V., Peris, Ketty, Chiricozzi A. (ORCID:0000-0002-6739-0387), Di Nardo L., Gori N., Caldarola G. (ORCID:0000-0002-8837-9232), De Simone C. (ORCID:0000-0002-0898-0045), Ippoliti E., and Peris K. (ORCID:0000-0002-5237-0463)

Abstract

Background: Tralokinumab is a human monoclonal antibody targeting interleukin-13 that is approved for the treatment of moderate-severe atopic dermatitis. Studies analyzing the efficacy and safety of tralokinumab in a real-world setting are scarce. Research design and methods: A European, multicentric, real-world, retrospective cohort study was defined to assess the effectiveness and safeness profile of tralokinumab, investigating the achievement of pre-specified treatment goals; and to detect potential differences in terms of effectiveness and safeness across some selected patient subcohorts. Results: A total of 194 adult patients were included in this study. A significant improvement in physician-assessed disease severity was detected at each follow-up visit as compared with baseline and similar trend was observed for patient-reported outcomes and quality of life. No meaningful difference in effectiveness was found when considering patient age (<65 versus ≥65 years), neither dissecting patient cohort in dupilumab-naive vs dupilumab-treated subjects. Among tralokinumab-treated patients, 88% achieved at least one currently identified real-world therapeutic goal at week 16. Conclusions: This retrospective multicenter study confirmed the effectiveness and safeness of tralokinumab throughout 32 weeks of observation, showing the achievement of therapeutic goals identified in both trial and real-world settings in a large proportion of tralokinumab-treated patients.

Published
2023

38. Topical ruxolitinib: A new treatment for vitiligo

Author

Tavoletti, G., primary, Avallone, G., additional, Conforti, C., additional, Roccuzzo, G., additional, Maronese, C. A., additional, Mattioli, M. A., additional, Quaglino, P., additional, Zalaudek, I., additional, Marzano, A. V., additional, Ribero, S., additional, and Alberti‐Violetti, S., additional

Published
2023
Full Text
View/download PDF

44. BRCA1-associated protein 1 c.368delG mutation leads to the development of multiple BAPomas and cutaneous melanomas: a novel pathogenic variant in BRCA1-associated protein tumor predisposition syndrome

Author

Cavallo, F., Roccuzzo, G., Merli, M., Avallone, G., Zocchi, L., Ogliara, P., Pasini, B., Quaglino, P., and Ribero, S.

Subjects
Cancer Research, Skin Neoplasms, Oncology, BRCA1 Protein, Mutation, Humans, Genetic Predisposition to Disease, Dermatology, Melanoma, Germ-Line Mutation
Published
2022
Full Text
View/download PDF

46. Current treatment goals are achieved by the majority of patients with atopic dermatitis treated with tralokinumab: results from a multicentric, multinational, retrospective, cohort study

Author

Chiricozzi, A, Ferrucci, SM, Di Nardo, L, Gori, N, Balato, A, Ortoncelli, M, Maurelli, M, Galluzzo, M, Munera Campos, M, Seremet, T, Caldarola, G, De Simone, C, Ippoliti, E, Torres, T, Gkalpakiotis, S, Conrad, C, Carrascosa, JM, Bianchi, L, Argenziano, G, Ribero, S, Girolomoni, G, Marzano, AV, and Peris, K

Abstract

ABSTRACTBackgroundTralokinumab is a human monoclonal antibody targeting interleukin-13 that is approved for the treatment of moderate-severe atopic dermatitis. Studies analyzing the efficacy and safety of tralokinumab in a real-world setting are scarce.Research design and methodsA European, multicentric, real-world, retrospective cohort study was defined to assess the effectiveness and safeness profile of tralokinumab, investigating the achievement of pre-specified treatment goals; and to detect potential differences in terms of effectiveness and safeness across some selected patient subcohorts.ResultsA total of 194 adult patients were included in this study. A significant improvement in physician-assessed disease severity was detected at each follow-up visit as compared with baseline and similar trend was observed for patient-reported outcomes and quality of life. No meaningful difference in effectiveness was found when considering patient age (<65 versus ≥65 years), neither dissecting patient cohort in dupilumab-naive vs dupilumab-treated subjects. Among tralokinumab-treated patients, 88% achieved at least one currently identified real-world therapeutic goal at week 16.ConclusionsThis retrospective multicenter study confirmed the effectiveness and safeness of tralokinumab throughout 32 weeks of observation, showing the achievement of therapeutic goals identified in both trial and real-world settings in a large proportion of tralokinumab-treated patients.

Published
2023
Full Text
View/download PDF

49. OS08.4.A Analysis of melanoma brain metastasis immune microenvironment through multiplex gene expression profiling

Author

Ricci, A A, primary, Collemi, G, additional, Orlando, G, additional, Tampieri, C, additional, Senetta, R, additional, Pellerino, A, additional, Bruno, F, additional, Melcarne, A, additional, Garbossa, D, additional, Rudà, R, additional, Soffietti, R, additional, Ribero, S, additional, Quaglino, P, additional, Cassoni, P, additional, and Bertero, L, additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results